<DOC>
	<DOCNO>NCT00384826</DOCNO>
	<brief_summary>To evaluate among patient untreated advanced ADC-CBA , impact disease control rate 4 month treatment early therapeutic permutation first month absence stabilization objective answer .</brief_summary>
	<brief_title>Therapeutic Strategy Advanced Bronchioloalveolar Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>CBA histologically proven ( cytologically pneumonic presentation ) PS &lt; 3 sign write informed consent visible tumoral lesion bronchial fibroscopy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Adenocarcinoma , Bronchiolo-Alveolar</keyword>
</DOC>